Omega-3 (EPA/DHA) dosage

Protocol

1. 1

   Measure the dose

   Typical Omega-3 (EPA/DHA) dose is 2000 mg (1 g/day EPA + DHA for general use; 2 to 4 g/day for triglyceride reduction or CV secondary prevention). Use a weight-based calculator for individual adjustments.

   Open tool →
2. 2

   Set the frequency

   Administer 1 to 2 times daily with food. Half-life of 48 hours anchors the dosing interval.

   Open tool →
3. 3

   Cycle if needed

   No cycling; continuous daily use is standard

   Open tool →
4. 4

   Monitor for side effects

   Watch for: fishy aftertaste; eructation (fish burps); mild dyspepsia; loose stools at high doses. Stop or reduce dose if tolerability breaks down.

Why this dose

Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function.

The typical dose (2000 mg) reflects 1 g/day EPA + DHA for general use; 2 to 4 g/day for triglyceride reduction or CV secondary prevention. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

Omega-3 (EPA/DHA) is administered via the oral route. Oral dosing is straightforward: take with water, with or without food unless specifically noted.

Onset of action runs around 4 hours after administration. Peak effect lands near 12 hours post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Plasma EPA/DHA half-life ~37 to 48 hours; tissue incorporation plateaus over 8 to 12 weeks of consistent dosing

Cycling and tolerance

No cycling; continuous daily use is standard

Effects to expect at typical dose

• Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
• REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
• Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
• Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
• Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
• Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state

Side effects and interactions

Common side effects

• fishy aftertaste
• eructation (fish burps)
• mild dyspepsia
• loose stools at high doses

Notable interactions

• warfarin and DOACs (moderate): additive antiplatelet effect at 2+ g/day; meaningful bleeding risk
• aspirin and antiplatelet agents (moderate): additive bleeding risk at high doses
• antiarrhythmics (moderate): high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia
• statins (minor): complementary cardiovascular effects; no pharmacokinetic interaction

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Omega-3 (EPA/DHA) profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

allowed

DEA / Rx

Not scheduled

Pregnancy

Recommended at 200 to 600 mg DHA/day for fetal development

Legal status

Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia

Do not use if

• fish allergy (use algal omega-3 alternative)
• active bleeding disorders
• scheduled surgery (discontinue 5-7 days prior)

Related research